Product image of Metformina + Vildagliptina Bluepharma (Metformin Hydrochloride, Vildagliptin) supplied by GNH India

Metformina + Vildagliptina Bluepharma

Active Ingredient:
Metformin Hydrochloride, Vildagliptin
Origin:
EU

Metformina + Vildagliptina Bluepharma (Metformin Hydrochloride, Vildagliptin)

Metformin hydrochloride and vildagliptin, the active ingredients in Metformina + Vildagliptina Bluepharma, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. They treat type 2 diabetes mellitus in adult patients.

GNH India supplies Metformina + Vildagliptina Bluepharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bluepharma Genéricos - Comércio De Medicamentos, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Vildagliptina is indicated for the management of type 2 diabetes mellitus and related metabolic disorders.

  • Type 2 diabetes mellitus: improves glycemic control when used alone or with other antidiabetic agents.
  • Metabolic syndrome (as part of diabetes management): helps lower fasting glucose and HbA1c levels.
  • Adjunct to diet and exercise: supports blood‑sugar regulation in adults with type 2 diabetes.

How It Works

  • Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, while vildagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to higher endogenous incretin levels that enhance glucose‑dependent insulin secretion and suppress glucagon release, together producing better overall glycaemic control.

Side Effects

The combination may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia.
  • Diarrhea: loose stools occurring especially after treatment initiation.
  • Headache: mild to moderate intensity.
  • Metallic taste: transient alteration in taste perception.
  • Fatigue: feeling of tiredness without obvious cause.
  • Skin rash: mild erythematous eruptions.

Serious or Rare Side Effects

  • Lactic acidosis: a rare but life‑threatening metabolic complication.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Acute pancreatitis: sudden inflammation of the pancreas.
  • Hepatic failure: marked liver enzyme elevation or dysfunction.
  • Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.
  • Anaphylactic reaction: rare systemic allergic response.

Precautions & Warnings

Before prescribing Metformina + Vildagliptina, clinicians should consider several safety factors.

  • Renal function: assess eGFR and avoid use in severe renal impairment.
  • Hepatic disease: evaluate liver function because lactic acidosis risk rises.
  • Hypoglycaemia risk: monitor closely when combined with insulin or sulfonylureas.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk.
  • Drug interactions: review concomitant medications for possible synergistic effects.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Metformina + Vildagliptina may interact with several medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of severe hypoglycaemia.
  • Iodinated contrast agents: may precipitate renal dysfunction with metformin.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise vildagliptin plasma levels.

Moderate Interactions (Monitor Closely)

  • Alcohol: potentiates risk of lactic acidosis.
  • Diuretics: may affect renal clearance of metformin, requiring dose adjustment.

Frequently Asked Questions

Metformina + Vildagliptina is a fixed‑dose oral antidiabetic medication indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose by improving insulin sensitivity and enhancing insulin secretion in response to meals.

Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral uptake of glucose, thereby lowering fasting and post‑prandial blood sugar levels. In the combination, it works alongside vildagliptin to provide complementary glucose‑lowering effects.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety in pregnancy and lactation has not been definitively established. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin alone, the addition of vildagliptin provides greater post‑prandial glucose control without the weight gain often seen with sulfonylureas. Unlike insulin, it is administered orally and carries a lower risk of severe hypoglycaemia when used as directed.

Metformina + Vildagliptina tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain product stability.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events include lactic acidosis, which is rare but potentially fatal, and severe hypoglycaemia when combined with insulin or sulfonylureas. Patients should be educated to recognize early symptoms and seek immediate medical attention if they occur.

The combination is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, and in those with a history of lactic acidosis. It should also be avoided in individuals with uncontrolled liver disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Vildagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT